Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA rejects Novartis gouty arthritis drug; seeks more safety data

This article was originally published in Scrip

Executive Summary

The US FDA took the advice of a June advisory panel to reject Novartis interleukin-1 betablocker canakinumab (ACZ885) as a treatment for gouty arthritis until the company can provide more data supporting the drug's benefit-risk profile in refractory patients.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC014238

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel